Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Histotype-specific incidence and survival of urothelial carcinoma-an analysis of the German North Rhine-Westphalia Cancer Registry.

ESMO real world data and digital oncology·2026
Same author

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

ESMO gastrointestinal oncology·2026
Same author

New targets of PET imaging for renal cancer.

Seminars in nuclear medicine·2025
Same author

GMP- compliant formulation and quality control of sodium [<sup>124</sup>I]iodide for oral applications.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2025
Same author

Shaping the future of <sup>177</sup>Lu-PSMA-617 radiopharmaceutical therapy in prostate cancer: is earlier better, or is patient selection key?

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Related Experiment Video

Updated: Aug 6, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K

Next generation radiotheranostics promoting precision medicine.

K L Pomykala1, B A Hadaschik2, O Sartor3

  • 1Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|March 16, 2023
PubMed
Summary
This summary is machine-generated.

Radiotheranostics, combining radiation and therapeutics, offers targeted treatments for cancers like thyroid, prostate, and neuroendocrine tumors. This review explores its fundamentals, clinical successes, and future directions, including new targets and artificial intelligence applications.

Keywords:
(177)Lu-DOTATATE(177)Lu-PSMAendoradiotherapypositron emission tomographyradiotheranosticstargeted radioligand therapy

More Related Videos

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

349
Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

893

Related Experiment Videos

Last Updated: Aug 6, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

349
Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

893

Area of Science:

  • Radiotheranostics leverages targeted radiation for cancer therapy and diagnosis.
  • This rapidly advancing field integrates nuclear medicine principles with targeted therapies.

Background:

  • Approved radiotheranostic agents include Iodine-131 for thyroid cancer, Radium-223 for bone metastases, Lutetium-177-DOTATATE for neuroendocrine tumors, and Lutetium-177-PSMA for prostate cancer.
  • Numerous other radiotheranostic agents are currently under investigation.

Purpose of the Study:

  • To provide a comprehensive review of the fundamentals of radiotheranostics.
  • To discuss key clinical studies, future developments, and challenges in the field.
  • To explore emerging considerations such as dosimetry and artificial intelligence in radiotheranostics.

Main Methods:

  • Review of existing literature on radiotheranostics, including approved treatments and clinical trials.
  • Analysis of current and future targets, radionuclides, and therapeutic platforms.
  • Discussion of logistical, reimbursement, dosimetry, and AI-related challenges and considerations.

Main Results:

  • Established radiotheranostic treatments demonstrate significant clinical success in specific cancers.
  • Ongoing research is expanding the scope of radiotheranostics with novel agents and targets.
  • Key challenges remain in logistics, reimbursement, and optimizing treatment strategies.

Conclusions:

  • Radiotheranostics represents a growing and effective approach to cancer treatment.
  • Future advancements will likely involve new targets, improved delivery platforms, and integration of AI.
  • Addressing logistical and clinical considerations is crucial for broader adoption and success.